Max Healthcare Institute Ltd — Q1 FY27 earnings call
Summary generated by AI from the official transcript Max Healthcare Institute Ltd filed with BSE on 05 Aug 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
At Max Healthcare's 25th AGM, management reported Network Gross Revenue of ₹10,538 crore for FY2025-26, up 16% year-on-year, with Operating EBITDA of ₹2,638 crore and profit after tax of ₹1,631 crore. The company disclosed the post-year-end acquisition of a 58.28% stake in Kalinga Hospital, Bhubaneswar, ongoing capacity expansion across multiple cities, and a net debt-to-EBITDA ratio below one. Shareholders raised questions on direct cost growth, bed capacity plans, loan increases, attrition, international business, and dividend policy, which management addressed during the Q&A.
Numbers mentioned
Network Gross Revenue: ₹10,538 crore (FY2025-26)
p. 7
“Our Network Gross Revenue increased to ₹10,538 crore, representing a healthy 16% year-onyear growth.”
Abhay Soi, page 7 of the filed PDF · View the filing
Operating EBITDA: ₹2,638 crore (FY2025-26)
p. 7
“Operating EBITDA reached ₹2,638 crore, while profit after tax stood at ₹1,631 crore, reflecting the resilience of our business model and the strength of our execution.”
Abhay Soi, page 7 of the filed PDF · View the filing
Profit after tax: ₹1,631 crore (FY2025-26)
p. 7
“Operating EBITDA reached ₹2,638 crore, while profit after tax stood at ₹1,631 crore, reflecting the resilience of our business model and the strength of our execution.”
Abhay Soi, page 7 of the filed PDF · View the filing
Free cash flow generated: ₹5,500 crore (last four years)
p. 17
“I just want to mention that we have generated free cash flow of around ₹5,500 crore in the last four years and we have invested a lot of it.”
Yogesh Kumar Sareen, page 17 of the filed PDF · View the filing
Loans taken: ₹1,400 crore (last 3 years)
p. 17
“So, I think all these loans that we have taken in last 3 years of around ₹1,400 crore has gone into creating capacity, which will generate a lot of funds going forward.”
Yogesh Kumar Sareen, page 17 of the filed PDF · View the filing
Net debt-to-EBITDA ratio: less than one
p. 17
“Currently, our net debt-to-EBITDA ratio is less than one.”
Yogesh Kumar Sareen, page 17 of the filed PDF · View the filing
Beds added: 1,250 beds (last three years)
p. 17
“We have acquired three hospitals. We also have added around 1,250 beds in the last three years.”
Yogesh Kumar Sareen, page 17 of the filed PDF · View the filing
Beds added (recent): close to 1,200 beds (last six months)
p. 18
“You've seen that we've expanded capacity in the last six months itself. We've increased capacity by close to 1,200 beds, which is about 20% of our overall capacity.”
Abhay Soi, page 18 of the filed PDF · View the filing
Bed capacity: around 6,000 beds
p. 17
“Two years ago, we were 3,500 beds and now we're already at around 6,000 beds.”
Abhay Soi, page 17 of the filed PDF · View the filing
Return on capital employed: northwards of 20-25%
p. 17
“And our return on capital employed is northwards of 20-25%.”
Abhay Soi, page 17 of the filed PDF · View the filing
Cost of borrowing: 7.5% to 8%
p. 17
“We get money at 7.5% to 8%.”
Abhay Soi, page 17 of the filed PDF · View the filing
Credit rating: CARE AA+; Stable
p. 17
“We are a CARE AA+; Stable rated Company.”
Abhay Soi, page 17 of the filed PDF · View the filing
Robotic surgery share of total surgeries: nearly 6%
p. 6
“Robotic procedures, which once represented a small fraction of our work, now account for nearly 6% of surgeries across our network and continue to grow at around 30% annually.”
Abhay Soi, page 6 of the filed PDF · View the filing
Free medical treatment provided: over ₹244 crores
p. 7
“Last year, we provided free medical treatment worth over ₹244 crores to approximately 3.6 lakh patients, reaffirming our belief that financial constraints should never become a barrier to quality healthcare.”
Abhay Soi, page 7 of the filed PDF · View the filing
CSR expenditure: ₹23.5 crores
p. 7
“Our CSR expenditure during the year stood at ₹23.5 crores, supporting a wide range of initiatives across healthcare, education, skill development and community empowerment.”
Abhay Soi, page 7 of the filed PDF · View the filing
Shares outstanding: 97.32 crore odd shares
p. 19
“I think we have 97.32 crore odd shares outstanding.”
Abhay Soi, page 19 of the filed PDF · View the filing
Final dividend: ₹2 per Equity Share of Face Value of ₹10 each (FY2025-26)
p. 8
“Declaration of Final Dividend of ₹2 per Equity Share of Face Value of ₹10 each, as an Ordinary Resolution.”
Dhiraj Aroraa, page 8 of the filed PDF · View the filing
Kalinga Hospital stake acquired: 58.28%
p. 5
“A major milestone after the close of the financial year was the acquisition of Kalinga Hospital Limited with a 58.28% stake.”
Abhay Soi, page 5 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
Bed capacity in the network — over 10,000 beds · FY30
stated firmly by Yogesh Kumar Sareen
p. 18
“So, by FY’30, will have over 10,000 beds in the Network.”
Yogesh Kumar Sareen, page 18 of the filed PDF · View the filing
Net debt-to-EBITDA leverage cap — 2.5 times
stated firmly by Abhay Soi
p. 17
“We intend to take leverage up to 2.5 times net debt-to-EBITDA.”
Abhay Soi, page 17 of the filed PDF · View the filing
Bed capacity — about 6,500 beds · before the end of the year
stated conditionally by Abhay Soi
p. 17
“I think before the end of the year, we should be about 6,500 beds.”
Abhay Soi, page 17 of the filed PDF · View the filing
Physical AGM — convene AGM physically · when Companies Amendment Bill 2026 is notified
stated conditionally by Dhiraj Aroraa
p. 19
“So, we would like to inform that the Company shall convene the AGM physically as and when Companies Amendment Bill 2026 is notified.”
Dhiraj Aroraa, page 19 of the filed PDF · View the filing
Entry into Hyderabad — expand presence to Hyderabad
stated as an aspiration by Yogesh Kumar Sareen
p. 18
“It's in the list of the 21 cities that we want to get in. But I think ‘when’ is only a question that we'll be able to let you know when it actually happens.”
Yogesh Kumar Sareen, page 18 of the filed PDF · View the filing
Direct cost normalization
stated as an aspiration by Abhay Soi
p. 18
“So, we don't see this as a structural increase, we see this more episodic than anything else and you will see this normalize as we move ahead.”
Abhay Soi, page 18 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
Management attributed the direct cost increase to lumpiness from recent capacity expansion and said it would normalize as occupancy ramps up.
Answered by Abhay Soi
Asked by Amit Ashok Thawani: When will direct costs, which grew faster than revenue in FY26, reverse?
p. 18
“When you have this sort of lumpiness in capacity expansion, you will also have lumpiness in direct costs because you're going to prepare for the rollout of that capacity.”
Abhay Soi, page 18 of the filed PDF · View the filing
Management explained the debt was used to fund growth investments and that the debt-to-EBITDA ratio remains well within acceptable limits.
Answered by Yogesh Kumar Sareen
Asked by Manjit Singh: What are the plans regarding the Company's rising loans?
p. 17
“This amount of ₹5,500 crores has been invested in the future growth of the Company.”
Yogesh Kumar Sareen, page 17 of the filed PDF · View the filing
Management said there is a robust credentialing process overseen by the Group Medical Director before doctors can practice.
Answered by Yogesh Kumar Sareen
Asked by Yash Pal Chopra: How does the Company ensure quality in credentialing doctors?
p. 17
“We have a Group Medical Director and a full team who actually credentials the doctors before they are really put in the hospital to do surgical procedures or even prescribe medicines.”
Yogesh Kumar Sareen, page 17 of the filed PDF · View the filing
Management said Hyderabad is on their expansion list but did not commit to a specific timeline.
Answered by Yogesh Kumar Sareen
Asked by Srikant Jhawar: When will Max Healthcare enter Hyderabad?
p. 18
“So, I think Hyderabad is one of the cities that we want to enter.”
Yogesh Kumar Sareen, page 18 of the filed PDF · View the filing
Management said attrition is relatively low compared to peers, with higher attrition among nurses than doctors.
Answered by Yogesh Kumar Sareen
Asked by Bimal Kumar Agarwal: What is the Company's attrition rate?
p. 18
“I think we are one of the best. We are one of the best companies in healthcare when it comes to attrition rate.”
Yogesh Kumar Sareen, page 18 of the filed PDF · View the filing
Management said the international business is growing faster than overall revenue and that a UK office has been set up to attract patients from developed markets.
Answered by Yogesh Kumar Sareen
Asked by Sarvjeet Singh: How is the Company's international business performing and is it targeting developed-country patients?
p. 18
“So, the international business is obviously doing better. It's growing better than the overall revenue growth.”
Yogesh Kumar Sareen, page 18 of the filed PDF · View the filing
Management said a stock split or bonus issue would not create shareholder value given adequate existing liquidity.
Answered by Abhay Soi
Asked by Gagan Kumar: Will the Company consider a bonus issue or stock split given the current share price?
p. 19
“I think having said that, splitting shares or issuing bonus shares does not lead to any enhancement of shareholder value since you're just splitting the same share.”
Abhay Soi, page 19 of the filed PDF · View the filing
Management clarified this assurance was undertaken voluntarily to strengthen disclosure credibility.
Answered by Dhiraj Aroraa
Asked by Prashant Kumar: Was the limited assurance on BRSR non-core indicators a legal requirement?
p. 19
“We would like to confirm that the Company has voluntarily conducted the limited assurance on noncore indicators as the independent assurance enhances the credibility and transparency of our disclosures and reflects our commitment to global reporting standards.”
Dhiraj Aroraa, page 19 of the filed PDF · View the filing
Risks flagged
Rising cost of medical talent due to more than 10,000 beds expected from private players entering the market
p. 10
“given that in the next two years, more than 10,000 plus bed capacity is expected to come into the market by private players, so, can this lead to an increased cost of medical talent and perhaps challenging to find the right medical talent?”
Ashwin Radheshyam Agarwal, page 10 of the filed PDF · View the filing
Leverage risk from borrowing to fund expansion, capped by management at a set ratio
p. 17
“Of course, having said that, there is a risk element to it and therefore we put a cap of 2.5 times net debt-to-EBITDA.”
Abhay Soi, page 17 of the filed PDF · View the filing
Episodic direct cost increases tied to lumpy capacity expansion
p. 18
“So, we don't see this as a structural increase, we see this more episodic than anything else and you will see this normalize as we move ahead.”
Abhay Soi, page 18 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.